129th AOAC Annual Meeting & Exposition Preliminary Program

SCIENTIFIC SESSIONS – MONDAY

Rapid Methods for Chemical Contamination: Cell Based assay, Spectroscopy, Portable Devices and Beyond Chemical contaminants such as mycotoxins and dioxins pose a major risk for human and animal health. Regulatory limits are established globally to reduce human and animal exposures to chemical hazards. Rapid assays for chemical contaminants play an indispensable role in regulatory frame work with regard to surveillance and compliance. Compared to classical chromatography or mass spectrometry based platforms, a variety of screening methods are less costly and present much higher throughput, which facilitates analyzing a large volume of samples in a rapid and eco- nomic fashion. Other advantages of rapid methods include enablement of on-site decision making by point-of-sampling tests. The strengths and weaknesses of the rapid methods will be elaborated and performance standards will be dis- cussed in the first presentation. In the second presentation, a non-main stream cell based assay for analyzing dioxin, a group of persistent environmental pollutants and highly toxic chemicals even at trace level concentrations (ppt) will be introduced. The classical assay for dioxins is the high resolution gas chromatography and mass spectrometry analysis, which is tedious and time consuming. CALAUX, a cell based bio assay has been developed and validated to screen dioxin at trace level concentrations. Furthermore, a field portable X-RAY fluorescence based platform will be presented for analyzing mercury in face cream products and providing reasonable agreeable results with the ICPMS analysis results. Finally, the feasibility of using a surface- enhanced Ramen spectroscopy based method to screen aflatoxin in maize from 0 to 1000 ug/kg concentration range will be presented. The session will offer audiences a broad spectrum of some non-mainstream rapid chemical screen- ing assays and their potential applications. CO-CHAIR: Michael McLaughlin, U.S. FDA CO-CHAIR: Susie Dai, Office of the Texas State Chemist • Susie Dai, Office of the Texas State Chemist Rapid Screening Methods: Pros, Cons and How Fast Do We Need Them? • George Clark, Xenobiotic Detection Systems CALUX: A Cell based Screening Assay for Dioxin and Dioxin-Like Chemicals • Pete Palmer, San Francisco State University Use of Field-Portable XRF Analyzers for Rapid Screening of Toxic Elements • Kyung-Min Lee, Office of the Texas State Chemist Surface-Enhanced Raman Spectroscopy for Rapid Detection of Aflatoxin in Maize

3:30 pm – 5:00 pm

Hot Topics in Cosmetics and Color Additives An increasingly global marketplace has resulted in many novel and complex challenges for the analysis of ingredients and contaminants (chemical and microbiological), and the analysis of color additives in foods and cosmetics. Consumers are as concerned about the chemical composition and safety of cosmetic products as they are about foods, both of which may be imported from a variety of countries as well as domestically produced. This has heightened interest in the alignment of regulatory requirements for the marketing of cosmetics and the international harmonization of scientific methods and standards. This AOAC Scientific Session provides initial briefings that speak to the challenges on both the regulatory and analytical scientific fronts, including the harmonization of analytical methods. This session is intended to further develop our AOAC Community on Cosmetics and Color additives. • Kenneth Kariasz, Johnson & Johnson Consumer Products, Inc. Analytical Test Method Challenges in Color Cosmetics • Sneh Bhandari, Silliker Inc. Determination of Permitted and Non-permitted Color Additives in Food Products • Marianita Perez Gonzalez, U.S. FDA Identification of Pigments in Tattoo Inks by X-ray Powder Diffraction, Raman Spectroscopy, and Liquid Chromatography • Kyson Chou, U.S. FDA Isolation and Identification of Nontuberculous Mycobacteria Associated with Tattoo-Related Outbreaks CO-CHAIR: Bhakti Petigara Harp, U.S. FDA CO-CHAIR: Thomas Hammack, U.S. FDA

11

September 27–30, 2015 |  Westin Bonaventure Hotel |  Los Angeles, California